Table 2.
The prevalence of resistant pathogens in clinical isolates from GCC countries
| Country |
Gram Negative |
Gram Positive |
||||||
|---|---|---|---|---|---|---|---|---|
| Acinetobacter | Escherichiacoli | Klebsiella pneumoniae | Pseudomonas aeruginosa | Clostridium difficile | Enterococcus | MRSA | Streptococcus pneumoniae | |
|
Bahrain |
N.R |
14.0% |
13.9% |
N.R |
N.R |
76.5% |
8.5% |
N.R |
|
Kuwait |
16.7% |
77.0% |
36.2% |
2.6% |
70.0% |
N.R |
3.3% |
66.3% |
|
Oman |
N.R |
N.R |
0.1% |
0.3% |
0.0% |
N.R |
58.3% |
N.R |
|
Qatar |
N.R |
1.1% |
0.8% |
0.6% |
N.R |
N.R |
N.R |
N.R |
|
Saudi Arabia |
83.3% |
7.6% |
48.3% |
92.3% |
30.0% |
23.5% |
29.9% |
30.7% |
| UAE | N.R | 0.3% | 0.7% | 4.2% | N.R | N.R | N.R | 3.0% |
GCC = Gulf Corporation Council; N.R = not reported; MRSA = methicillin resistant Staphylococcus aureus; UAE = United Arab Emirates.